301 related articles for article (PubMed ID: 28903571)
1. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
[TBL] [Abstract][Full Text] [Related]
2. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
Brozova L; Schwarz D; Snabl I; Kalina J; Pavlickova B; Komenda M; Jarkovský J; Němec P; Horinek D; Stefanikova Z; Pour L; Hájek R; Maisnar V
Klin Onkol; 2017; 30(Supplementum2):43-50. PubMed ID: 28903570
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
4. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
7. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Sandecká V; Hájek R; Pour L; Špička I; Ščudla V; Gregora E; Radocha J; Walterová L; Kessler P; Zahradová L; Adamová D; Valentova K; Vonke I; Obernauerová J; Starostka D; Wróbel M; Brožová L; Jarkovský J; Mikulášová A; Říhová L; Ševčíková S; Straub J; Minařík J; Adam Z; Krejčí M; Král Z; Maisnar V;
Eur J Haematol; 2017 Jul; 99(1):80-90. PubMed ID: 28384387
[TBL] [Abstract][Full Text] [Related]
8. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
13. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
14. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
16. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit.
Bumma N; Nagasaka M; Hemingway G; Miyashita H; Chowdhury T; Kim S; Vankayala HM; Ahmed S; Jasti P
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):305-311. PubMed ID: 32144026
[TBL] [Abstract][Full Text] [Related]
17. Asymptomatic monoclonal gammopathies.
Bories C; Jagannath S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S78-86. PubMed ID: 25486961
[TBL] [Abstract][Full Text] [Related]
18. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
